

For the Patent Owner
Backup counsel: Robert W. Hahl, Reg. No. 33,893
Backup counsel: Robert Mihail, Reg. No. 66,021
Neifeld IP Law, PC

Paper No. __

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Coalition For Affordable Drugs V LLC
Petitioner

v.

Biogen MA Inc.
Patent Owner

Case IPR Unassigned
Patent 8,399,514
Title: TREATMENT FOR MULTIPLE SCLEROSIS

PETITIONER'S EXHIBIT LIST

37 CFR 42.63(e) states that:

(e) *Exhibit list.* Each party must maintain an exhibit list with the exhibit number and a brief description of each exhibit. If the exhibit is not filed, the exhibit list should note that fact. A current exhibit list must be served whenever evidence is served and the current exhibit list must be filed when filing exhibits.

Description of Marks in the Date Served, and Date Filed columns:

A date in the "Date Served" column indicates the exhibit has been served on the specified date.

A date in the "Date Filed" column indicates the exhibit has been filed on the specified date.

Exhibit Number	Description of Exhibit	Not Served	Date Served	Not Filed	Date Filed
1001	US Patent No. 8,399,514, titled "Treatment for Multiple Sclerosis" to Lukashev et al. ('514 patent)		5/1/2015		5/1/2015
1002	Unassigned				
1003	Kappos et al., "A randomised, placebo-controlled phase II trial of a novel oral single-agent fumarate therapy, BG00012, in patients with relapsing-remitting multiple sclerosis", 2005, J Neurol (2005) 252 [Suppl 2]: II/95–II/170, pII/148, P574.		5/1/2015		5/1/2015

Exhibit Number	Description of Exhibit	Not Served	Date Served	Not Filed	Date Filed
1004	International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Dose-Response Information to Support Drug Registration E4, Current Step 4 version, dated 10 March 1994.		5/1/2015		5/1/2015
1005	Declaration of Dr. Steven E. Linberg.		5/1/2015		5/1/2015
1006	Unassigned				
1007	“Preliminary Amendment Under 37 C.F.R. § 1.115, In re application of: LUKASHEV et al.”, Application No. 13/372,426 that issued into US Patent 8,399,514.		5/1/2015		5/1/2015
1008	“Amendment and Reply Under 37 C.F.R. § 1.111, In re application of: LUKASHEV et al., Appl. No. 13/372,426” that issued into US Patent 8,399,514.		5/1/2015		5/1/2015
1009	Office Action with mail date of 05/03/2012 for Application No. 13/372,426 that issued into US Patent 8,399,514.		5/1/2015		5/1/2015

Exhibit Number	Description of Exhibit	Not Served	Date Served	Not Filed	Date Filed
1010	Unassigned				
1011	PCT Application No. PCT/US2008/001602		5/1/2015		5/1/2015
1012	Certified copy of US Provisional Application No. 601888,921		5/1/2015		5/1/2015
1013	Assignment Record for US Patent No. 8,399,514 from USPTO's Assignments on the Web.		5/1/2015		5/1/2015
1014	IFW of PCT/US2008/001602.		5/1/2015		5/1/2015
1015	Certified Copy of US Provisional 60/888,921 as received by the International Bureau on March 26, 2008.		5/1/2015		5/1/2015
1016	D. Werdenberg, et al., "Presystemic Metabolism and Intestinal Absorption of Antipsoriatic Fumaric Acid Esters", 2003, BIOPHARMACEUTICS & DRUG DISPOSITION, Biopharm. Drug Dispos. 24: 259-273 (2003), Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/bdd.364.		5/1/2015		5/1/2015

Exhibit Number	Description of Exhibit	Not Served	Date Served	Not Filed	Date Filed
1017	CV of Dr. Steven E. Linberg		5/1/2015		5/1/2015
1018	US Application 13/372,426, as filed on February 13, 2012		5/1/2015		5/1/2015
1019	Nieboer et al., "Fumaric Acid Therapy in Psoriasis: A Double-Blind Comparison between Fumaric Acid Compound Therapy and Monotherapy with Dimethylfumaric Acid Ester" Dermatologica 1990; 181:33- 37		5/1/2015		5/1/2015
1020	Declaration of Scott Bennett		5/1/2015		5/1/2015
1021	"BG 12 BG 00012, BG 12/Oral Fumarate, FAG-201, Second-Generation Fumarate Derivative – Fumapharm/ Biogen Idec", 2005, Drugs R D 2005; 6 (4): 229-230.		5/1/2015		5/1/2015
1022	"View of NCT00168701 on 2005_09_14", from URL https://clinicaltrials.gov/archive/NCT00168701/2005_09_14		5/1/2015		5/1/2015
1023	"Galenic development", Fumapharm AG archival page located at http://web.archive.org/web/20050803080203/http://www.fumapharm.ch/EN/Research/Galenical_Development/index.php		5/1/2015		5/1/2015

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.